HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meller, J. Articles by Scheel, A. K. Search for Related Content PubMed PubMed Citation Articles by Meller, J. Articles by Scheel, A. K.

¹⁸F-FDG PET and PET/CT in Fever of Unknown Origin^*

¹ Department of Nuclear Medicine, University of Göttingen, Göttingen, Germany; and ² Department of Nephrology and Rheumatology, University of Göttingen, Göttingen, Germany

Correspondence: For correspondence or reprints contact: Johannes Meller, MD, Department of Nuclear Medicine, University of Göttingen, Robert Koch-Straße 40, D-37075, Germany. E-mail: jmeller{at}med.uni-goettingen.de

Fever of unknown origin (FUO) was originally defined as recurrent fever of 38.3°C or higher, lasting 2–3 wk or longer, and undiagnosed after 1 wk of hospital evaluation. The last criterion has undergone modification and is now generally interpreted as no diagnosis after appropriate inpatient or outpatient evaluation. The 3 major categories that account for most FUOs are infections, malignancies, and noninfectious inflammatory diseases. The diagnostic approach in FUO includes repeated physical investigations and thorough history-taking combined with standardized laboratory tests and simple imaging procedures. Nevertheless, there is a need for more complex or invasive techniques if this strategy fails. This review describes the impact of ¹⁸F-FDG PET in the diagnostic work-up of FUO. ¹⁸F-FDG accumulates in malignant tissues but also at the sites of infection and inflammation and in autoimmune and granulomatous diseases by the overexpression of distinct facultative glucose transporter (GLUT) isotypes (mainly GLUT-1 and GLUT-3) and by an overproduction of glycolytic enzymes in cancer cells and inflammatory cells. The limited data of prospective studies indicate that ¹⁸F-FDG PET has the potential to play a central role as a second-line procedure in the management of patients with FUO. In these studies, the PET scan contributed to the final diagnosis in 25%–69% of the patients. In the category of infectious diseases, a diagnosis of focal abdominal, thoracic, or soft-tissue infection, as well as chronic osteomyelitis, can be made with a high degree of certainty. Negative findings on ¹⁸F-FDG PET essentially rule out orthopedic prosthetic infections. In patients with noninfectious inflammatory diseases, ¹⁸F-FDG PET is of importance in the diagnosis of large-vessel vasculitis and seems to be useful in the visualization of other diseases, such as inflammatory bowel disease, sarcoidosis, and painless subacute thyroiditis. In patients with tumor fever, diseases commonly detected by ¹⁸F-FDG PET include Hodgkin's disease and aggressive non-Hodgkin's lymphoma but also colorectal cancer and sarcoma. ¹⁸F-FDG PET has the potential to replace other imaging techniques in the evaluation of patients with FUO. Compared with labeled white blood cells, ¹⁸F-FDG PET allows diagnosis of a wider spectrum of diseases. Compared with ⁶⁷Ga-citrate scanning, ¹⁸F-FDG PET seems to be more sensitive. It is expected that PET/CT technology will further improve the diagnostic impact of ¹⁸F-FDG PET in the context of FUO, as already shown in the oncologic context, mainly by improving the specificity of the method.

Key Words: FDG • PET/CT • fever of unknown origin • FUO • infection • inflammation

^* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH JANUARY 2008.

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				F. Breibach, A. Julian, C. Laurent, E. Anglade, A. Constantin, N. Sans, J.-L. Tricoire, P. Brousset, M.-B. Delisle, and A. Gomez-Brouchet Contribution of the 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography to the diagnosis of primary osseous Hodgkin lymphoma BMJ Case Reports, May 25, 2009; 2009(may25_1): bcr0820080696 - bcr0820080696. [Abstract] [Full Text]

				M. Zhang, X. Jiang, M. Zhang, H. Xu, G. Zhai, and B. Li The Role of 18F-FDG PET/CT in the Evaluation of Ascites of Undetermined Origin J. Nucl. Med., April 1, 2009; 50(4): 506 - 512. [Abstract] [Full Text] [PDF]

				A. M. Groves, T. Win, N. J. Screaton, M. Berovic, R. Endozo, H. Booth, I. Kayani, L. J. Menezes, J. C. Dickson, and P. J. Ell Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with 18F-FDG PET/CT J. Nucl. Med., April 1, 2009; 50(4): 538 - 545. [Abstract] [Full Text] [PDF]

				Z. Keidar, A. Gurman-Balbir, D. Gaitini, and O. Israel Fever of Unknown Origin: The Role of 18F-FDG PET/CT J. Nucl. Med., December 1, 2008; 49(12): 1980 - 1985. [Abstract] [Full Text] [PDF]

				H. Hautzel, O. Sander, A. Heinzel, M. Schneider, and H.-W. Muller Assessment of Large-Vessel Involvement in Giant Cell Arteritis with 18F-FDG PET: Introducing an ROC-Analysis-Based Cutoff Ratio J. Nucl. Med., July 1, 2008; 49(7): 1107 - 1113. [Abstract] [Full Text] [PDF]